Valuation : Personalis, Inc.

Market Cap 183.7Cr 158.07Cr 148.72Cr 135.86Cr 254.15Cr 17TCr 254.84Cr 1.76TCr 681.95Cr 8.9TCr 689.8Cr 674.75Cr 29TCr P/E 2026 *
-15.7x
P/E 2027 * -18.3x
Enterprise Value 165.94Cr 142.79Cr 134.34Cr 122.72Cr 229.58Cr 16TCr 230.2Cr 1.59TCr 616.02Cr 8.04TCr 623.11Cr 609.52Cr 26TCr EV / Sales 2026 *
20.1x
EV / Sales 2027 * 15.8x
Free-Float
73.85%
Yield 2026 *
-
Yield 2027 * -
1 day+2.20%
1 week+0.76%
Current month+2.50%
1 month+27.22%
3 months+60.00%
6 months+100.93%
Current year+116.08%
1 week 16.44
Extreme 16.44
17.38
1 month 13.13
Extreme 13.13
18.89
Current year 4.96
Extreme 4.955
18.89
1 year 4.96
Extreme 4.955
18.89
3 years 0.89
Extreme 0.8906
18.89
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 02/03/2023
Chief Executive Officer 65 31/12/2022
President 55 13/03/2026
Director TitleAgeSince
Director/Board Member 79 01/05/2019
Chairman 76 17/05/2022
Director/Board Member 72 06/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Exercice

Chairperson

3,00,000 0.2865%
09/07/26 Exercice

Chief Executive Officer

3,00,000 0.2865%
29/06/26 Exercice

Chief Financial Officer

14,946 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
+2.20%+0.76%+228.24%+961.73% 183.7Cr
-2.54%-2.84%-1.77%+14.72% 4.89TCr
-0.40%+1.03%+418.57%+523.39% 4.5TCr
-1.42%+2.30%+42.67%+21.22% 4.41TCr
-1.22%-2.31%+4.82%+74.90% 4.07TCr
+0.53%-1.36%+16.87%+47.12% 3.35TCr
-0.21%+9.14% - - 1.78TCr
-0.35%-1.56%+21.42%+123.04% 1.65TCr
-1.01%+0.50%+13.91%+31.45% 1.47TCr
-1.65%-1.03%+75.93%+41.22% 1.38TCr
Average -0.61%+0.56%+91.18%+204.31% 2.77TCr
Weighted average by Cap. -1.01%+0.11%+90.40%+133.84%

Financials

2026 *2027 *
Net sales 8.25Cr 7.1Cr 6.68Cr 6.1Cr 11Cr 778.62Cr 11Cr 79Cr 31Cr 399.48Cr 31Cr 30Cr 1.29TCr 11Cr 9.48Cr 8.92Cr 8.15Cr 15Cr 1.04TCr 15Cr 105.43Cr 41Cr 533.84Cr 41Cr 40Cr 1.72TCr
Net income -12Cr -9.9Cr -9.32Cr -8.51Cr -16Cr -1.09TCr -16Cr -110.11Cr -43Cr -557.55Cr -43Cr -42Cr -1.8TCr -10Cr -8.77Cr -8.25Cr -7.54Cr -14Cr -962.58Cr -14Cr -98Cr -38Cr -493.87Cr -38Cr -37Cr -1.59TCr
Net Debt -18Cr -15Cr -14Cr -13Cr -25Cr -1.68TCr -25Cr -169.91Cr -66Cr -860.33Cr -67Cr -65Cr -2.77TCr -9.1Cr -7.83Cr -7.37Cr -6.73Cr -13Cr -859.56Cr -13Cr -87Cr -34Cr -441.01Cr -34Cr -33Cr -1.42TCr
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
04/26/04 $17.20 +2.20% 25,22,867
03/26/03 $16.83 +0.60% 24,94,050
02/26/02 $16.73 -1.93% 22,27,164
01/26/01 $17.06 +1.67% 36,19,033
31/26/31 $16.78 -1.70% 28,45,863
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
17.20USD
Average target price
15.44USD
Spread / Average Target
-10.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock